Clinical Trial

JAK Signaling in Depression

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will test the hypothesis that Janus kinase (JAK) signaling is involved in major depression (MD) with high inflammation by determining whether its inhibition with baricitinib can improve functional connectivity in reward and motor circuits in association with improved motivation and motor function in MD patients enriched for high C-reactive protein (CRP) and anhedonia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-26; most recent amendment 2025-09-11.
Status change: Not Yet Recruiting → Recruiting 2025-09-11
Trial Details
NCT Number NCT07003997
Lead Sponsor Emory University
Collaborators: National Institute of Mental Health (NIMH)
Conditions Major Depressive Disorder
Enrollment 100 participants
Start Date 2025-09-03
Primary Completion 2030-02 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2025-09-15